| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2010 | US7700595 such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) |
| 04/20/2010 | US7700594 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer |
| 04/20/2010 | US7700593 Imidazo- and triazolo-pyridine compounds and methods of use thereof |
| 04/20/2010 | US7700592 phenylmorpholine and phenylthiomorpholine compounds for treatment of allergic rhinitis, congestion, pain, diarrhea, glaucoma, congestive heart failure, cardiac ischemia, manic disorders, depression, anxiety, migraine, stress-induced urinary incontinence, neuronal damage from ischemia and schizophrenia |
| 04/20/2010 | US7700591 to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis |
| 04/20/2010 | US7700590 Antibacterial agents |
| 04/20/2010 | US7700589 Such as 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(3,4-diethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide; calcitonin gene related peptide (CGRP); for treatment of migraines; radioimmunoassay |
| 04/20/2010 | US7700588 Pharmaceutical compositions comprising midazolam in a high concentration |
| 04/20/2010 | US7700587 Haloperidol analogs |
| 04/20/2010 | US7700586 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 04/20/2010 | US7700585 Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics |
| 04/20/2010 | US7700584 antitumor agents; viricides |
| 04/20/2010 | US7700583 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| 04/20/2010 | US7700582 Pharmaceutical formulation |
| 04/20/2010 | US7700581 3-((1,2,5,6-tetrahydro-2-methyl-5,6-d ioxo-1,2,4-triazine-3-yl)thio)methyl)-7-[[[[[(1-methyl ethyl)amino][(1-methylethyl)imino]methyl]thio]acetyl]amino]-8-oxo-5-thia-1-aza-bicyclo [4.2.0]oct-2-ene-2-carboxylic acid; bioavailibility; stability; pharmacokinetics; antibiotics; infections |
| 04/20/2010 | US7700579 Process for the preparation of piroxicam: b-cyclodextrin inclusion compounds |
| 04/20/2010 | US7700578 A vaccine to prevent diarrhea by administering an immunogenic capsulated polysaccharide based on repeating units of an O-methyl phosphoramidated heptose disaccharide without concomitantly inducing Barre-Guillain Syndrome; bioconjugating with a carrier to effect enhanced T-cell dependent immunity |
| 04/20/2010 | US7700577 Bactericides for antibiotic-resistant Micrococcus, Streptococcus, Enterococcus or Staphylococcus; pure saccharide antibiotics; 4-((3-(trifluoromethyl-)phenyl)-amino-carbonylamino-),4,5-(dihydroxy-),6-(hydroxymethyl-)tetrahydropyran-2-yl)-),5-(undecanoylamino-),6-(hydroxymethyl-)tetrahydropyran |
| 04/20/2010 | US7700576 Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium |
| 04/20/2010 | US7700575 Methods of treating ocular conditions |
| 04/20/2010 | US7700573 Method for diagnosing non-small lung cancer |
| 04/20/2010 | US7700570 Oligonucleotide mediated specific cytokine induction and prophylaxis and treatment of viral infection in a mammal |
| 04/20/2010 | US7700569 Single- or double-stranded stabilized DNA contains nonmethylated octameric CG motif of the sequence AACGTTAT (nucleotides 9-16 of SEQ ID NO: 9); phosphorothioate oligonucleotides; nuclease inhibitors; immunostimulants; nontoxic; anticarcinogenic agents; intratumoral administration; nervous systems |
| 04/20/2010 | US7700567 Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| 04/20/2010 | US7700566 Creation of an aqueous environment having greater than about 2% of sugars such as dextrose, sucrose and fructose in varying ratios; mosquito larvae fail to develop beyond the second instar stage prolonging period for the larval stage; upation and development into adulthood is reduced; nontoxic |
| 04/20/2010 | US7700563 Synthetic heparin-binding factor analogs |
| 04/20/2010 | US7700562 Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring |
| 04/20/2010 | US7700561 Abuse-resistant amphetamine prodrugs |
| 04/20/2010 | US7700554 Compositions for modulating blood-brain barrier transport |
| 04/20/2010 | US7700552 Macrocyclic inhibitors of hepatitis C virus |
| 04/20/2010 | US7700547 Preventing airway mucus production by administration of EGF-R antagonists |
| 04/20/2010 | US7700545 Use of NF-κB inhibition in combination therapy for cancer |
| 04/20/2010 | US7700543 Use NF-κB inhibition in combination therapy for cancer |
| 04/20/2010 | US7700331 produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production |
| 04/20/2010 | US7700320 Schizochytrium fatty acid synthase (FAS) and products and methods related thereto |
| 04/20/2010 | US7700315 Comprises nucleotide sequences coding polypeptide with serine protease activity for use in identifying modulator and treaments for blood coagulation and cell proliferative disorders |
| 04/20/2010 | US7700280 Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer |
| 04/20/2010 | US7700274 Compositions and methods in cancer associated with altered expression of KCNJ9 |
| 04/20/2010 | US7700134 Side effect reduction; administering sodium selenite and,or amifostine |
| 04/20/2010 | US7700131 Powders having contact biocidal properties |
| 04/20/2010 | US7700128 a layer containing pioglitazone or pioglitazone hydrochloride; and a layer containing glimepiride and a polyoxyethylene sorbitan fatty acid ester ; useful as a diabetes-treating agent and excellent in the dissolution properties of an insulin sensitizer and an insulin releasing pills |
| 04/20/2010 | US7700125 Moisture resistant container systems for rapidly bioavailable dosage forms |
| 04/20/2010 | US7700122 Topical compositions comprising an opioid analgesic and an NMDA antagonist |
| 04/20/2010 | US7700120 Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus |
| 04/20/2010 | US7700106 Therapeutic agent for ulcerative colitis |
| 04/20/2010 | US7700091 Bacterium for use as vehicle for gene transport and transfer to preferential organs or tissues; tissue engineering and targeted somatic transgenesis |
| 04/20/2010 | US7700088 Interleukin-9 mutein peptides |
| 04/20/2010 | US7700087 Compounds and methods to inhibit or augment an inflammatory response |
| 04/20/2010 | US7700086 Internal clamp for surgical procedures |
| 04/20/2010 | US7700085 Administering an agent which inhibits binding of advanced glycation endproducts to any of their receptors; wound healing |
| 04/20/2010 | US7700084 Cosmetic composition with skin tightening effect |
| 04/20/2010 | US7700083 Skin care composition for accelerated production of collagen proteins and method of fabricating same |
| 04/20/2010 | US7700082 Silylated polyurethane-urea compositions for use in cosmetic applications |
| 04/20/2010 | US7700081 Psoriasis; applying daily to hair an aqueous mixture of clobetasol propionate, an anionic surfactant, an amphoteric surfactant, and ethanol; leaving it for 2.5 to 15 minutes, and rinsing with water. |
| 04/20/2010 | US7700080 Oxidation resistance; aging resistance; skin disorders |
| 04/20/2010 | US7700079 natural soap bar for cleaning the skin, comprising titanium dioxide and zinc oxide sunscreen agents; providing protection against sunlight; also contains balm of Gilead, chlorophyll, olive oil, aloe vera, and lemon juice; protection of skin |
| 04/20/2010 | US7700076 alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from urea, hydroxy acid and a therapeutic enhancer and a propellant; foam further comprises active agents and excipients |
| 04/20/2010 | US7700074 Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| 04/20/2010 | US7700073 Use of NF-κB inhibition in combination therapy for cancer |
| 04/20/2010 | US7699609 Dispensing apparatus and cartridge with deformable tip |
| 04/20/2010 | CA2584974C Drug and food or drink for improving pancreatic functions |
| 04/20/2010 | CA2581865C Indazolone derivatives as 11b-hsd1 inhibitors |
| 04/20/2010 | CA2572898C Composition for the prevention and treatment of allergic inflammatory disease |
| 04/20/2010 | CA2565411C Compounds and methods for inhibiting mitotic progression |
| 04/20/2010 | CA2561950C 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 04/20/2010 | CA2515366C Compositions and methods to modulate immune and inflammatory responses |
| 04/20/2010 | CA2510540C Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 04/20/2010 | CA2495146C Oil composition |
| 04/20/2010 | CA2494067C Hetero biaryl derivatives as matrix metalloproteinase inhibitors |
| 04/20/2010 | CA2485600C 5-ht4 receptor antagonists for the treatment of heart failure |
| 04/20/2010 | CA2448829C Preparation for the removal of abnormal keratinous material |
| 04/20/2010 | CA2448356C N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 04/20/2010 | CA2447926C Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle |
| 04/20/2010 | CA2438509C Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria |
| 04/20/2010 | CA2438506C Use of a cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications |
| 04/20/2010 | CA2437697C Parasiticidal compositions and methods of use |
| 04/20/2010 | CA2433915C Improved controlled release oral dosage form |
| 04/20/2010 | CA2433409C Use of mglur5 antagonists for the treatment of pruritic conditions |
| 04/20/2010 | CA2433335C Particles for inhalation having sustained release properties |
| 04/20/2010 | CA2432178C Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
| 04/20/2010 | CA2426764C Nateglinide-containing hydrophilic pharmaceutical preparation |
| 04/20/2010 | CA2425338C Compositions comprising modafinil compounds |
| 04/20/2010 | CA2419880C 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1h)one derivatives |
| 04/20/2010 | CA2418744C Novel aminocyclohexane derivatives |
| 04/20/2010 | CA2417935C Anti-inflammatory medicament |
| 04/20/2010 | CA2417475C Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacterien |
| 04/20/2010 | CA2410579C Methods and compositions for treating flaviviruses and pestiviruses |
| 04/20/2010 | CA2408528C Creatine salt having enhanced nutritional and therapeutic efficacy and compositions containing same |
| 04/20/2010 | CA2400172C Nanocapsule encapsulation system and method |
| 04/20/2010 | CA2393159C Methods of treating tumors |
| 04/20/2010 | CA2388240C Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 04/20/2010 | CA2386826C Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for peritoneal dialysis |
| 04/20/2010 | CA2362331C Epoxide hydrolase complexes and methods therewith |
| 04/20/2010 | CA2361587C Methods and compositions to enhance white blood cell count |
| 04/20/2010 | CA2361307C Ectoparasite control compositions |
| 04/20/2010 | CA2359573C Conjugates of colony stimulating factors for targeting and imaging infection and inflammation |
| 04/20/2010 | CA2358925C Compositions and methods for use in targeting vascular destruction |
| 04/20/2010 | CA2348741C Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use |
| 04/20/2010 | CA2319680C Compounds and compositions for delivering active agents |
| 04/20/2010 | CA2279331C Compounds and compositions for delivering active agents |